A Study to Compare the Safety and Efficacy of Two Ranibizumab Dosing Regimens in a Turkish Cohort of Patients With Choroidal Neovascularization Secondary to AMD
Latest Information Update: 29 Apr 2016
Price :
$35 *
At a glance
- Drugs Ranibizumab (Primary)
- Indications Choroidal neovascularisation
- Focus Therapeutic Use
- 29 Apr 2016 New trial record